IMMATICS NV

ARYA Sciences Acquisition Corp. (Nasdaq: ARYA), sponsored by Perceptive Advisors, completed its initial public offering in 2019 with a focus on the biopharmaceutical sector. In March 2020, ARYA announced a definitive business combination with Immatics NV, a clinical-stage oncology company co-headquartered in Tübingen, Germany and Houston, Texas, developing T cell-redirecting therapies including TCR bispecifics and adoptive cell therapies aimed at solid tumors. The transaction closed in 2020, with Immatics subsequently trading on Nasdaq under the ticker IMTX. The deal was among the earlier high-profile SPAC mergers in the cancer immunotherapy space. Sign up at SpacDesk for full data on ARYA and hundreds of other SPAC transactions.

SPAC Counterparty (1)